Definium Therapeutics Shares Surge 60% After Psychedelic Depression Drug Trial Success
Shares in Definium Therapeutics Inc. surged as much as 60% on Monday after the company released late-stage clinical trial data for its experimental psychedelic treatment for major depressive disorder. The results were described as "groundbreaking" by the company. Definium is a psychedelic drug developer focused on treatments for mental health conditions.
Comments
No comments yet — be the first to weigh in 👇
No comments yet. Be the first!